US › Healthcare

Pasithea Therapeutics Corp (KTTA)

US · Healthcare · Biotechnology

$0.51+3.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.3M

EPS

$-0.16

EPS estimate

$-0.16

EPS came in at -0.16 against a street estimate of -0.16 — a beat of 0.0%.

Key statistics

Market cap

$18.0M

Forward P/E

0.0

P/B

0.38

Book value

$1.49

EPS (TTM)

$-1.35

52-week high

$2.06

52-week low

$0.28

50-day MA

$0.50

200-day MA

$0.74

Beta

0.33

Analyst view

Analysts rate Pasithea Therapeutics Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders

1.11%

Institutions

63.23%

Largest institutional holders

Fund	Stake
HHG PLC	6.28%
Adage Capital Partners Gp LLC	6.28%
Opaleye Management Inc	6.14%
Ameriprise Financial Inc	4.04%
Cable Car Capital LLC	3.61%
Squadron Capital Management LLC	2.99%
AdvisorShares Investments, LLC	2.81%
Stonepine Capital Management Llc	2.49%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pasithea Therapeutics Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.